Nephrotoxicity secondary to CDK 4/6 inhibitors in advanced breast cancer patients and its impact on survival.

ABSTRACT:

Background

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have become a cornerstone in the treatment of HR+/HER2- advanced breast cancer. While their efficacy is well-established, emerging reports of nephrotoxicity warrant further investigation into its incidence, risk factors, and potential impact on survival outcomes.

Objectives

This study aimed to evaluate the incidence and risk factors for nephrotoxicity in patients receiving CDK4/6 inhibitors (palbociclib or ribociclib) and to analyze its association with progression-free survival (PFS) and overall survival (OS).

Design

This was a single-center, retrospective cohort study.

Methods

We reviewed the medical records of 120 patients with advanced breast cancer treated with palbociclib or ribociclib between Oct

SUBMITTER: Avci T 

PROVIDER: S-EPMC12789390 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature